These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E; Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854 [TBL] [Abstract][Full Text] [Related]
10. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. Moschonas IC; Goudevenos JA; Tselepis AD Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282 [TBL] [Abstract][Full Text] [Related]
11. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348. Macaulay TE; Allen C; Ziada KM Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225 [TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Becker RC; Moliterno DJ; Jennings LK; Pieper KS; Pei J; Niederman A; Ziada KM; Berman G; Strony J; Joseph D; Mahaffey KW; Van de Werf F; Veltri E; Harrington RA; Lancet; 2009 Mar; 373(9667):919-28. PubMed ID: 19286091 [TBL] [Abstract][Full Text] [Related]
13. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. TRA*CER Executive and Steering Committees Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853 [TBL] [Abstract][Full Text] [Related]
14. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. White HD Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598 [TBL] [Abstract][Full Text] [Related]
15. Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent. Lee S Arch Pharm Res; 2011 Apr; 34(4):515-7. PubMed ID: 21544715 [TBL] [Abstract][Full Text] [Related]
16. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. Tomasello SD; Angiolillo DJ; Goto S Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570 [TBL] [Abstract][Full Text] [Related]
17. Atopaxar. A novel player in antiplatelet therapy? Wurster T; May AE Hamostaseologie; 2012; 32(3):228-33. PubMed ID: 22859265 [TBL] [Abstract][Full Text] [Related]
18. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. Shinohara Y; Goto S; Doi M; Jensen P J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374 [TBL] [Abstract][Full Text] [Related]
19. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075 [TBL] [Abstract][Full Text] [Related]
20. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. Franchi F; Rollini F; Park Y; Angiolillo DJ Future Cardiol; 2015 Sep; 11(5):547-64. PubMed ID: 26406386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]